Barrett's Dysplasia Detection Pilot Trial Using the NvisionVLE® Imaging System

NinePoint Medical150 enrolled

Overview

The NvisionVLE® Dysplasia Detection Pilot Study is a prospective, non-randomized trial for participants who have a prior biopsy-confirmed diagnosis of BE with dysplasia and are scheduled to have an endoscopic evaluation of your esophagus for BE surveillance by a standard procedure called EGD (esophagogastroduodenoscopy) as well as an imaging procedure called VLE (volumetric laser endomicroscopy).

The NvisionVLE® Dysplasia Detection Pilot Study is a collection of data for research. Participation is completely voluntary and does not affect the patient's medical care that chooses not to participate. The purpose of this Study is to determine the performance of the NvisionVLE® Imaging System in determining features of dysplastic Barrett's Esophagus (BE). This is done by the collection and analysis of the medical record information, imaging data, and pathology results. The information is then stored and may be used at a later time for various future analyses and publications. Any future analyses involving this Study will only use the information collected in this Study. No further involvement or additional informed consent of participants will be needed if future analyses are performed. This Study is designed for participants who have a prior biopsy-confirmed diagnosis of BE with dysplasia and are scheduled to have an endoscopic evaluation of your esophagus for BE surveillance by a standard procedure called EGD (esophagogastroduodenoscopy) as well as an imaging procedure called VLE (volumetric laser endomicroscopy). The NvisionVLE® Imaging System is cleared for use by the U.S. Food and Drug Administration (FDA). Patients who undergo an endoscopic evaluation of the esophagus with the NvisionVLE® Imaging System at participating hospitals will be invited to participate in this Study. The Study is taking place at up to 4 hospitals, and as many as 100 patients may participate in this Study.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

150

Conditions

Barrett's Esophagus

Interventions

NvisionVLE with Real Time TargetingDEVICE

Physician will complete a VLE scan of the esophagus and target areas of interest using the VLE optical marking probe

esophagogastroduodenoscopy (EGD)PROCEDURE

Standard of care EGD

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients over the age of 18. * Patients undergoing an upper endoscopy for BE surveillance with prior biopsy-confirmed BE with dysplasia (at least LGD). * Ability to provide written, informed consent. * No significant esophagitis (LA grade \< B, C and D). Exclusion Criteria: * Patients who have achieved complete remission of intestinal metaplasia (CR-IM) * Patients without visible BE at time of study EGD. * Patients for whom use of the NvisionVLE device would be in conflict with the Instructions for Use (IFU). * Prior esophageal or gastric surgical resection. * Significant esophageal stricture requiring dilatation. * Patients who require anticoagulation for whom biopsy would be contraindicated. * Patients who are known to be pregnant.

Locations (5)

UC Irvine Medical Center

Irvine, California, United States

VA Boston

Boston, Massachusetts, United States

Mayo Clinic

Rochester, Minnesota, United States

North Shore University Hospital

Manhasset, New York, United States

Outcomes

Primary Outcomes

Performance of manually identified VLE features in predicting biopsy defined dysplasia

To determine the per-biopsy performance of a multivariable model consisting of manually-identified VLE features for predicting biopsy-defined dysplasia

Time frame: Up to 2 years post data collection

Secondary Outcomes

Per Patient Sensitivity and specificity for detecting dysplasia

1\. To determine the absolute per-patient sensitivity and specificity of a multivariable model consisting of manually-identified VLE features for predicting biopsy-defined dysplasia.

Time frame: Up to 2 years post data collection

Per Biopsy Sensitivity and specificity for detecting dysplasia

2\. To determine the absolute per-biopsy sensitivity and specificity of a multivariable model consisting of manually-identified VLE features for predicting biopsy-defined dysplasia.

Time frame: Up to 2 years post data collection

Per Biopsy performance of VLE compared to standard-of-care for detecting dysplasia

3\. To compare, on a per-biopsy basis, the performance of VLE and standard-of-care to standard-of-care alone in detecting dysplasia.

Time frame: Up to 2 years post data collection

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.